ClinicalTrials.Veeva

Find clinical trials for Ovarian Cancer in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Toronto, ON, CAN:

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)

This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-s...

Enrolling
Ovarian Cancer
Drug: BA3021
Drug: To be determined

Phase 2

Canadian Cancer Trials Group

Toronto, Ontario, Canada and 6 other locations

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Durvalumab placebo
Drug: Bevacizumab

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 213 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Olaparib 300mg tablets
Drug: Placebo to match olaparib 300mg

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 125 other locations

The goal of this clinical trial is to test alternative dosing of niraparib in patients with newly diagnosed high-grade, advanced stage ovarian...

Enrolling
Stage III Ovarian Cancer
High Grade Ovarian Serous Adenocarcinoma
Drug: Niraparib

Phase 2

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Drug: carboplatin
Drug: carboplatin

Phase 2

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 41 other locations

be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the saf...

Active, not recruiting
Recurrent Epithelial Ovarian Cancer
Recurrent Peritoneal Cancer
Drug: Epacadostat (INCB024360)
Drug: Cyclophosphamide

Phase 1, Phase 2

Immunovaccine

Toronto, Ontario, Canada and 8 other locations

mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in...

Invitation-only
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Pegylated Liposomal Doxorubicin + SL-172154
Drug: Mirvetuximab + SL-172154

Phase 1

Shattuck Labs

Toronto, Ontario, Canada and 23 other locations

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Toronto, Canada and 46 other locations

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Pegylated liposomal doxorubicin (PLD)
Drug: Olaparib

Phase 3

Novartis
Novartis

Toronto, Ontario, Canada and 93 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 176 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems